News Releases
Jun 17, 2022
Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Additional Formats
May 26, 2022
Lyra Therapeutics to Present at Upcoming Investor Conferences
Additional Formats
May 10, 2022
Lyra Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
Additional Formats
May 05, 2022
Lyra Therapeutics to Present at Upcoming Investor Conferences
Additional Formats
Apr 29, 2022
Lyra Therapeutics Presents Positive Data from LANTERN Phase 2 Study of LYR-210 for Treatment of Chronic Rhinosinusitis at COSM 2022
Additional Formats
Apr 25, 2022
Lyra Therapeutics Announces First Patient Treated in Phase 2 BEACON Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients
Additional Formats
Apr 21, 2022
Lyra Therapeutics Announces Two Presentations at Upcoming COSM 2022
Additional Formats
Apr 13, 2022
Lyra Therapeutics Announces Closing of $100.5 Million Private Placement
Additional Formats
Apr 08, 2022
Lyra Therapeutics Announces $100.5 Million Private Placement
Additional Formats
Mar 09, 2022
Lyra Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
Additional Formats
Displaying 1 - 10 of 14